IOPAMIDOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H22I3N3O8
Molecular Weight	777.086
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@]([H])(C(=Nc1c(c(c(c(c1I)C(=NC(CO)CO)O)I)C(=NC(CO)CO)O)I)O)O

InChI

InChIKey=XQZXYNRDCRIARQ-LURJTMIESA-N

InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf
Curator's Comment:: description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8c18c9-3e7d-4515-b980-120025a88fc1 http://www.rxlist.com/isovue-drug.htm

Iopamidol is a nonionic, low-osmolar iodinated contrast agent. Iopamidol is indicated for angiography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography, and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents. Intravascular injection of contrast media is frequently associated with the sensation of warmth and pain especially in peripheral arteriography and venography. In angiocardiography the adverse reactions are: hot flashes, angina pectoris, flushing, bradycardia, hypotension, hives.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Target ID: vessels and anatomical structures Sources: http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?37/56/38797?source=see_link#F7914497	Activator 1329

Conditions

Condition	Modality	Highest Phase	Product
Cardiovascular diseases 70 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf	Diagnostic	Approved 7968	ISOVUE-M 300 Approved Use ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date 5.04835211E11
Urinary system disease 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf	Diagnostic	Approved 7968	ISOVUE-M 300 Approved Use ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date 5.04835211E11
Glioma 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf	Diagnostic	Approved 7968	ISOVUE-M 300 Approved Use ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date 5.04835211E11

C_max

Value	Dose	Co-administered	Analyte	Population
112.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096110	15 mL single, intrathecal dose: 15 mL route of administration: Intrathecal experiment type: SINGLE co-administered:		IOPAMIDOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
931 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096110	15 mL single, intrathecal dose: 15 mL route of administration: Intrathecal experiment type: SINGLE co-administered:		IOPAMIDOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018735s054lbl.pdf	single, intravenous		IOPAMIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9084958			IOPAMIDOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
61 % single, intravenous Dose: 61 % Route: intravenous Route: single Dose: 61 % Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: disseminated lupus erythematosus manifested mainly by lupus nephritis, computed tomography Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/	Disc. AE: Hepatotoxicity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/
612 mg/mL single, intrathecal Dose: 612 mg/mL Route: intrathecal Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/	unknown, 45 years n = 1 Health Status: unknown Condition: cervical myelography Age Group: 45 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/	Disc. AE: Generalized tonic-clonic seizure... AEs leading to discontinuation/dose reduction: Generalized tonic-clonic seizure (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/
54250 mg single, intravenous Dose: 54250 mg Route: intravenous Route: single Dose: 54250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (18 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
62775 mg single, intravenous Dose: 62775 mg Route: intravenous Route: single Dose: 62775 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (5 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
68544 mg single, intravenous Dose: 68544 mg Route: intravenous Route: single Dose: 68544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (23 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
69768 mg single, intravenous Dose: 69768 mg Route: intravenous Route: single Dose: 69768 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (32 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
83700 mg single, intravenous Dose: 83700 mg Route: intravenous Route: single Dose: 83700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
87516 mg single, intravenous Dose: 87516 mg Route: intravenous Route: single Dose: 87516 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (46 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
88740 mg single, intravenous Dose: 88740 mg Route: intravenous Route: single Dose: 88740 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (42 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (69 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (74 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
61225 mg/mL single, intravenous Dose: 61225 mg/mL Route: intravenous Route: single Dose: 61225 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (8 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (8 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (26 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/

AEs

AE	Significance	Dose	Population
Hepatotoxicity	1 patient Disc. AE	61 % single, intravenous Dose: 61 % Route: intravenous Route: single Dose: 61 % Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: disseminated lupus erythematosus manifested mainly by lupus nephritis, computed tomography Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/
Generalized tonic-clonic seizure	1 patient Disc. AE	612 mg/mL single, intrathecal Dose: 612 mg/mL Route: intrathecal Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/	unknown, 45 years n = 1 Health Status: unknown Condition: cervical myelography Age Group: 45 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/
Extravasation	18 patients	54250 mg single, intravenous Dose: 54250 mg Route: intravenous Route: single Dose: 54250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Extravasation	5 patients	62775 mg single, intravenous Dose: 62775 mg Route: intravenous Route: single Dose: 62775 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Extravasation	23 patients	68544 mg single, intravenous Dose: 68544 mg Route: intravenous Route: single Dose: 68544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Extravasation	32 patients	69768 mg single, intravenous Dose: 69768 mg Route: intravenous Route: single Dose: 69768 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	3 patients	83700 mg single, intravenous Dose: 83700 mg Route: intravenous Route: single Dose: 83700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	46 patients	87516 mg single, intravenous Dose: 87516 mg Route: intravenous Route: single Dose: 87516 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	42 patients	88740 mg single, intravenous Dose: 88740 mg Route: intravenous Route: single Dose: 88740 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	69 patients	612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	74 patients	612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	8 patients	61225 mg/mL single, intravenous Dose: 61225 mg/mL Route: intravenous Route: single Dose: 61225 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	8 patients	775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	26 patients	775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31711	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31711
ChemicalBook	CB5384796	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5384796
MolPort	MolPort-003-848-224	https://www.molport.com/shop/molecule-link/MolPort-003-848-224
ZINC	ZINC000003830947	http://zinc15.docking.org/substances/ZINC000003830947
eMolecules	31588820	https://www.emolecules.com/cgi-bin/more?vid=31588820
eMolecules	36753566	https://www.emolecules.com/cgi-bin/more?vid=36753566

PubMed

Title	Date	PubMed
[Iotrolan versus iopamidol. A controlled double-blind study with lumbar myelography].	1992 Aug	1410326
The role of early radiological studies after gastric bariatric surgery.	2001 Aug	11501353
Selective nerve root blocks for the treatment of sciatica: evaluation of injection site and effectiveness--a study with patients and cadavers.	2001 Dec	11719666
Ionic and non-ionic contrast agent-mediated endothelial injury. Quantitative analysis of cell proliferation during endothelial repair.	2001 Jul	11442469
Comparison of effects of ioxaglate versus iomeprol on histamine and tryptase release in patients with ischemic cardiomyopathy.	2001 Jul 15	11448422
[Severe thrombocytopenia induced by radiographic non-ionic contrast medium].	2001 Jun	11505531
Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.	2001 Jun	11410750
Assessment of Fallopian tube patency by HyCoSy: comparison of a positive contrast agent with saline solution.	2001 Nov	11844177
Effects of hematocrit and blood flow distribution on solute clearance in hollow-fiber hemodialyzers.	2001 Nov	11598384
Differential effects of radiocontrast agents on human umbilical vein endothelial cells: cytotoxicity and modulators of thrombogenicity.	2001 Nov 20	11726305
[Doppler evaluation of thyroid hemodynamics after intravenous administration of contrast media].	2001 Nov-Dec	11779984
Is a routine liquid contrast swallow following laparoscopic gastric banding mandatory?	2001 Oct	11594102
Diagnostic accuracy of computed tomography for cervical metastases at different anatomical levels in carcinoma of the tongue.	2001 Sep	11571542
Fast 3D dynamic MR imaging of the liver with MR SmartPrep: comparison with helical CT in detecting hypervascular hepatocellular carcinoma.	2001 Sep-Oct	11682296
Pericaval fat collection mimicking an intracaval lesion on CT in patients with chronic liver disease.	2001 Sep-Oct	11503086
Acute occlusion of coronary artery bypass graft with nonionic contrast medium.	2002 Apr	11993202
Usefulness of multislice computed tomography for detecting obstructive coronary artery disease.	2002 Apr 15	11950427
Enhanced radio sensitivity with iodinated contrast agents using monochromatic synchrotron X-rays on human cancerous cells.	2002 Aug	12188332
Optimization of contrast agent administration in MSCT angiography.	2002 Aug	12188276
cAMP and cGMP do not mediate the vasorelaxation induced by iodinated radiographic contrast media in isolated swine renal arteries.	2002 Jan	11972472
[Value of triple phase helical CT for the detection of hepatocellular carcinoma in cirrhotic liver].	2002 Jan	11793293
Toxic epidermal necrolysis incriminating iopamidol in a child after cardiac catheterization.	2002 Jan	11786169
[Method of injection of contrast medium for brain perfusion CT].	2002 Jul	12515965
Optimum iodine concentration of contrast material through microcatheters: hydrodynamic analysis of experimental results.	2002 Jul 21	12171337
Iodinated contrast medium-induced potassium release: the effect of mixing ratios.	2002 Jul-Aug	12296436
Effects of iodinated contrast and field strength on gadolinium enhancement: implications for direct MR arthrography.	2002 Mar	11891980
New RES-specific contrast agents for CT.	2002 May	12019864
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].	2002 Nov-Dec	12722628
Aortic and hepatic enhancement and tumor-to-liver contrast: analysis of the effect of different concentrations of contrast material at multi-detector row helical CT.	2002 Sep	12202710
[CO2 angiography of transplanted kidneys].	2003	12650035
Effects of contrast media on erythrocyte aggregation during sedimentation.	2003 Apr	12769231
Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?	2003 Apr	12697241
Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media.	2003 Apr	12690428
Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bone marrow transplantation.	2003 Feb	12563132
Visualization of breast lymphatic pathways with an indirect computed tomography lymphography using a nonionic monometric contrast medium iopamidol: preliminary results.	2003 Feb	12544070
Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.	2003 Feb 5	12578487
Usefulness of electron beam tomography in the prone position for detecting atrial thrombi in chronic atrial fibrillation.	2003 Jan-Feb	12544247
[Successful use of transvenous angio-multidetector-CT in diagnosing cecal angiodysplasia as the cause of peranal hemorrhage].	2003 Jun	12811701
[Feasibility and optimization of the combined injection of contrast medium and normal saline with a single-syringe CT injection system].	2003 Jun	12811699
Three-dimensional CT angiography of the hepatic artery: use of multi-detector row helical CT and a contrast agent.	2003 Jun	12773687
Nonionic contrast media are less nephrotoxic than ionic contrast media to rat renal cortical slices.	2003 Jun 5	12697376
Delayed side effects induced by iodinated contrast media, especially those associated with iodixanol.	2003 Mar	12659083
Assessment of pancreatic CT enhancement using a high concentration of contrast material.	2003 Mar-Apr	12816354
Sonographic versus magnetic resonance arthrographic evaluation of full-thickness rotator cuff tears in millimeters.	2003 Mar-Apr	12700560
Simultaneous voiding cystourethrography and voiding urosonography.	2003 May	12751996
Cartilage lesions in the ankle joint: comparison of MR arthrography and CT arthrography.	2003 May	12682790
CT arthrography of the glenohumeral joint: CT fluoroscopy versus conventional CT and fluoroscopy--comparison of image-guidance techniques.	2003 Oct	12944606
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study.	2003 Oct	12944602
Fate of pharmaceuticals--photodegradation by simulated solar UV-light.	2003 Sep	12871743
Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector-row helical CT.	2003 Sep	12736754

Patents

Sample Use Guides

In Vivo Use Guide

Peripheral Arteriograghy: For injection into the femoral artery or subclavian artery, 5 to 40 mL of ISOVUE-300 may be used; for injection into the aorta for a distal runoff, 25 to 50 mL may be used. Doses up to a total of 250 mL of ISOVUE-300 have been administered during peripheral arteriography.

Route of Administration: Intravascular

In Vitro Use Guide

Diffusion of iopamidol (300 and 200 mgI/ml) was studied in the cerebrospinal fluid (CSF). Test tubes containing CSF were kept in a waterbath at 37 degrees C. Contrast medium was injected along the wall into the tubes, and diffusion of contrast media in the tubes was followed with repeated computed tomography for 5 h. The contents of the tubes were then mixed by shaking, and the tubes were scanned immediately and 8 h later.

Name

Type

Language

IOPAMIDOL

Official Name

English

IOPAMIDOL [ORANGE BOOK]

Common Name

English

IOPAMIDOL [EP MONOGRAPH]

Common Name

English

IOPAMIDOL [USAN]

Common Name

English

IOPAMIDOL [WHO-DD]

Common Name

English

IOPAMIDOL [VANDF]

Common Name

English

SQ-13396

Code

English

(S)-N,N'-BIS(2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)-2,4,6-TRIIODO-5-LACTAMIDOISOPHTHALAMIDE

Systematic Name

English

IOPAMIDOL [USP MONOGRAPH]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)-5-((2-HYDROXY-1-OXOPROPYL)AMINO)-2,4,6-TRIIODO-, (S)-

Common Name

English

ISOVUE

Brand Name

English

IOPAMIDOL [INN]

Common Name

English

IOPAMIDOL [EP]

Common Name

English

SQ 13,396

Code

English

IOPAMIDOL [MI]

Common Name

English

IOPAMIRON

Brand Name

English

IOPAMIDOL [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28500